Overview

PVSRIPO With/Without Lomustine

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

This is a randomized phase 2 study of oncolytic polio/rhinovirus recombinant (PVSRIPO) alone or in combination with the chemotherapy drug lomustine in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.

Phase:

Phase 2

Details

Lead Sponsor:

Darell D. Bigner, MD, PhD

Treatments:

Lomustine